Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis
Kaiming Tao, Philip L. Tzou, Sergei L. Kosakovsky Pond, John P. A. Ioannidis, Robert W. Shafer
Abstract
susceptibility of the two main Omicron variants BA.1 and BA.2 to therapeutic MAbs in advanced clinical development, including eight authorized individual MAbs and three authorized MAb combinations. We estimated the degree to which different MAbs displayed reduced activity against Omicron variants. The marked loss of activity of many MAbs against Omicron variants underscores the importance of developing MAbs that target conserved regions of spike. Highly disparate results between assays indicate the need for improved MAb susceptibility test standardization.
Topics & Concepts
Monoclonal antibodyMeta-analysisSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakVirologyAntibodyBiologyGeneticsMedicineInternal medicineDiseaseOutbreakInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchBacillus and Francisella bacterial researchSARS-CoV-2 detection and testing